China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd, a fellow Chinese firm, for a consideration of RMB 186.8 million. This strategic move is aimed at bolstering Northeast Pharmaceutical’s presence in the cell therapy sector.
Dingcheng Peptide Source’s Background and Focus
Founded in 2014, Dingcheng Peptide Source has been dedicated to the development and translation of cell therapies targeting solid tumors. The company has an impressive portfolio of over 10 cell therapy products designed to treat a range of cancers, including pancreatic, colorectal, gastric, liver, and glioma. Their therapies encompass TCR-T, TCR, and innovative CAR-T therapies, with targets such as KRAS mutations, EGFRvIII, AFP, and Claudin18.2.
Translational Platform and Clinical Trials
Dingcheng Peptide Source also operates a comprehensive translation platform that encompasses plasmid technology, virus technology, cell technology, and quality research. A significant milestone for the company is its DCTY1102, a TCR-T therapy that targets KRAS G12D. This therapy has been tacitly approved for clinical trials in China for the treatment of advanced pancreatic cancer, colorectal cancer, and other malignant solid tumors.- Flcube.com
